EUCTR2005-005660-86-GB进行中（未招募）不适用
A Phase II, open label, single arm study to evaluate Ticilimumab in Advanced Gastric/Oesophageal Adenocarcinoma
Christie Hospital NHS Trust0 个研究点开始时间: 2006年7月23日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •To be eligible for the study, patients must satisfy all of the following criteria:
- •1. Histologically confirmed gastric or oesophageal adenocarcinoma that is locally advanced or metastatic.
- •2. Prior treatment with appropriate chemotherapy.
- •3. Patients with persistent or progressive disease post chemotherapy or patients who could not tolerate previous treatment due to unacceptable toxicity.
- •4. A minimum of one measurable lesion on CT scan according to RECIST. See Appendix 2 for details.
- •5. ECOG performance status (PS) 0 or 1.
- •6. Life expectancy > 3 months.
- •7. Age = 18 years.
- •8. Female patients must be surgically sterile or be postmenopausal for at least two years, or must agree to use effective contraception during the period of treatment and 6 months after. Women of child bearing potential must have a negative pregnancy test prior to entry and within 72 hours prior to receiving each cycle of ticilimumab.
- •9. Adequate bone marrow, hepatic and renal function determined within 14 days prior to enrollment, defined as:
- •Absolute neutrophil count = 1.5 x 109 cells/L
- •Platelets = 100 x 109 cells/L
- •Haemoglobin = 9.0g/dL
- •Aspartate and Alanine aminotransferases (AST, ALT) = 2.5 x ULN 5 x ULN if documented liver metastases are present)
- •Total bilirubin = 2 x ULN (except for patients with documented Gilbert’s syndrome)
- •Serum creatinine =170µmol/L
- •10. Patients must have recovered from all prior treatment-related toxicities, to baseline status, or to NCI CTCAE v3 Grade 0 or 1, except for toxicities not considered a safety risk such as alopecia or residual peripheral neuropathy resulting from prior systemic therapy. Post-surgical pain shall not be considered a basis for exclusion.
- •11. Must be willing and able to provide written informed consent.
- •12. Must be willing and able to comply with Study procedures
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years)
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Received treatment for cancer within 4 weeks prior to enrollment (dosing), 12 weeks for immunotherapy.
- •2. Received any prior anti-CTLA4-inhibiting agent.
- •3. History of, or significant evidence of risk for, chronic inflammatory or autoimmune disease (eg Addison’s disease, multiple sclerosis, Graves disease, Hashimoto’s thyroiditis, inflammatory bowel disease, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, hypophysitis, pituitary disorders etc.). Vitiligo will not be a basis for exclusion.
- •4. History of, or clinically apparent hepatitis B or hepatitis C.
- •5. History of inflammatory bowel disease, celiac disease or other chronic gastrointestinal conditions associated with diarrhoea or bleeding, or current acute colitis of any origin.
- •6. Potential requirement for systemic corticosteroids or concurrent immunosuppressive drugs based on prior history or received systemic steroids within the last 4 weeks prior to enrollment (Note: inhaled or topical steroids in standard doses are allowed).
- •7. Known brain metastases.
- •8. Prior or concurrent malignancy within the last 5 years other than basal cell carcinoma or in situ carcinoma of the uterine cervix.
- •9. Evidence of uncontrolled cardiac or respiratory disease or other serious medical or psychiatric disorders that would be a contra-indication to study procedures.
- •10. Evidence of significant clinical disorder or laboratory finding which, in the opinion of the investigator makes it undesirable for the patient to participate in the study.
- •11. Pregnancy or breast-feeding.
研究者
相似试验
进行中（未招募）
1 期
A Phase 2, open label, single arm study to evaluate the efficacy, safety, tolerability and pharmacokinetics of ticilimumab in patients with advanced refractory and/or relapsed melanoma - N/AMalignant MelanomaMedDRA version: 8.0 Level: VTc Classification code 10025650EUCTR2005-002826-70-GBPfizer Inc., 235 East 42nd Street, New York, 10017, USA215
招募中
1 期
A global study of midostaurin in combination with chemotherapy to evaluate safety, efficacy, and pharmacokinetics in newly diagnosed pediatric patients with FLT3-mutated AMuntreated FLT3-mutated Acute Myeloid LeukemiaMedDRA version: 21.0Level: LLTClassification code: 10000886Term: Acute myeloid leukemia Class: 10029104CTIS2023-509834-20-00ovartis Pharma AG29
招募中
不适用
The study to evaluate the safety, efficacy, and pharmacokinetics of twice daily midostaurin (PKC412) combined with standard chemotherapy and as a single agent post-consolidation therapy in children with untreated FLT3-mutated AMDiseases of the blood and blood -forming organs and certain disorders involving the immune mechanismKCT0004051ovartis Korea4
进行中（未招募）
1 期
A phase II, open-label, single arm study to evaluate the efficacy ofLuspatercept in Erythropoiesis-stimulating agent naive lower-riskMDS patients with or without ring sideroblasts who do not requireRBC transfusionsCTIS2024-516438-36-00niversitaet Leipzig30
进行中（未招募）
1 期
A Phase II, open-label, single arm study to evaluate the safety, efficacy, and pharmacokinetics of twice daily midostaurin (PKC412) combined with standard chemotherapy and as a single agent post-consolidation therapy in children with untreated FLT3-mutated AMuntreated FLT3-mutated acute myeloid leukemiaMedDRA version: 21.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864EUCTR2017-004830-28-DEovartis Pharma AG23